Antibiotic-Induced Changes to the Host Metabolic Environment Inhibit Drug Efficacy and Alter Immune Function

Yang, Jason H.; Bhargava, Prerna; McCloskey, Douglas; Mao, Ning; Palsson, Bernhard; Collins, James J.

Published in:
Cell Host & Microbe

Link to article, DOI:
10.1016/j.chom.2017.10.020

Publication date:
2017

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Antibiotic-Induced Changes to the Host Metabolic Environment Inhibit Drug Efficacy and Alter Immune Function

Highlights

- Antibiotic treatment depletes central metabolism intermediates in the peritoneum
- Antibiotic treatment elicits microbiome-independent changes in host metabolites
- Metabolites altered by antibiotic treatment during infection inhibit drug efficacy
- Antibiotic treatment impairs phagocytic killing by inhibiting respiratory activity

In Brief

Antibiotic susceptibility is sensitive to metabolites, but how this affects in vivo treatment efficacy remains unexplored. Yang, Bhargava et al. characterize antibiotic-induced changes to the metabolic environment during infection and find that direct actions of antibiotics on host cells induce metabolites that impair drug efficacy and enhance phagocytic activity.

Authors

Jason H. Yang, Prerna Bhargava, Douglas McCloskey, Ning Mao, Bernhard O. Palsson, James J. Collins

Correspondence

jimjc@mit.edu

Yang et al., 2017, Cell Host & Microbe 22, 757–765

December 13, 2017 © 2017 Elsevier Inc.

https://doi.org/10.1016/j.chom.2017.10.020
Antibiotic-Induced Changes to the Host Metabolic Environment Inhibit Drug Efficacy and Alter Immune Function

Jason H. Yang, Prema Bhargava, Douglas McCloskey, Ning Mao, Bernhard O. Palsson, and James J. Collins

SUMMARY

Bactericidal antibiotics alter microbial metabolism as part of their lethality and can damage mitochondria in mammalian cells. In addition, antibiotic susceptibility is sensitive to extracellular metabolites, but it remains unknown whether metabolites present at an infection site can affect either treatment efficacy or immune function. Here, we quantify local metabolic changes in the host microenvironment following antibiotic treatment for a peritoneal Escherichia coli infection. Antibiotic treatment elicits microbiome-independent changes in local metabolites, but not those distal to the infection site, by acting directly on host cells. The metabolites induced during treatment, such as AMP, reduce antibiotic efficacy and enhance phagocytic killing. Moreover, antibiotic treatment impairs immune function by inhibiting respiratory activity in immune cells. Collectively, these results highlight the immunomodulatory potential of antibiotics and reveal the local metabolic microenvironment to be an important determinant of infection resolution.

INTRODUCTION

Although the mechanisms of action for most conventional antibiotics have been well studied (Kohanski et al., 2010), the effects of antibiotic treatment on human physiology and host-microbe interactions are only beginning to be understood (Willing et al., 2011). Antibiotics have been observed to alter immune responses (Anuforom et al., 2015), and there is growing appreciation that non-specific actions by antibiotics may promote disease by creating favorable niches for opportunistic pathogens (Theriot et al., 2014). In light of the pressing challenges of antibiotic resistance and the diminishing drug discovery pipeline (Brown and Wright, 2016), there is an urgent need to better understand the complex consequences of antibiotic treatment during infection.

We have previously shown that bacterial metabolism participates in the efficacy of bactericidal antibiotics (Belenky et al., 2015; Dwyer et al., 2014; Lobritz et al., 2015) and that antibiotic susceptibility is sensitive to extracellular metabolites (Allison et al., 2011; Meylan et al., 2017). During infection, bacterial pathogens dynamically remodel their metabolic environment by inducing host catabolism, disrupting metabolic balance, and altering the abundance of energy metabolites, amino acids, and lipids (Beisel, 1975; Dong et al., 2012). However, it remains unknown how local changes to the metabolic microenvironment might also alter antibiotic efficacy during treatment.

Here, we sought to determine whether antibiotic treatment alters the host metabolic microenvironment and whether such changes alter antibiotic susceptibility or immune function. We performed targeted metabolomics on samples from mice receiving oral antibiotics for a peritoneal infection and found that antibiotic treatment systemically alters metabolites in the host, depleting central metabolism intermediates in the peritoneum. We show that these changes are microbiome independent as they also occur in germ-free (GF) mice. Additionally, we demonstrate that metabolites altered by antibiotic treatment during infection may inhibit antibiotic efficacy and potentiate the phagocytic activity of immune cells. Moreover, we show that antibiotics directly inhibit respiratory activity in immune cells and can consequently impair their phagocytic activity. Together, these results indicate that antibiotic-induced changes to host metabolites and metabolic processes can significantly affect both treatment efficacy and immune function.
**RESULTS**

**Antibiotic Treatment Depletes Central Metabolism Intermediates in the Peritoneum**

To determine whether antibiotics alter metabolites in the host environment, we quantified metabolites in samples from mice receiving antibiotic treatment, bacterial infection, or their combination. We subjected a cohort of 8-week-old C57BL/6J mice to receiving antibiotic treatment, bacterial infection, or their combination. After 24 hr, mice were euthanized and samples from three tissues were collected for metabolomic profiling: (1) the peritoneum, to characterize changes in metabolites local to infection; (2) plasma, to characterize global changes in circulating metabolites; and (3) the lung, to characterize changes in metabolites distal to infection. We performed targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) on these samples (McCloskey et al., 2015), enabling absolute quantification for nearly 80 metabolites supporting bacterial growth, including amino acids, nucleotides, and central metabolism intermediates (Table S1).

Hierarchical clustering of these measurements revealed that the metabolomic profiles clustered first by tissue, then by perturbation (Figure 1B), indicating that the metabolic changes elicited by antibiotic treatment or infection were local and tissue specific. Unsupervised principal component analysis (PCA) revealed that antibiotic treatment systemically altered metabolites in the host environment as samples from ABX mice clustered away from control (CTL) samples in all three tissues (Figures 1C, S1A, and S1B). In contrast, infection only exerted local changes, eliciting significant changes in metabolites in the peritoneum (Figure 1C), but not in the plasma (Figure S1A) or lung (Figure S1B).

To better understand the antibiotic-induced changes in the infection microenvironment, we performed multivariate analysis on the peritoneal samples to identify a metabolite signature corresponding to antibiotic treatment. We applied elastic net regularization and partial least-squares discriminant analysis (PLS-DA) and identified a feature set of metabolites that could discriminate the ABX samples from the union of CTL and INF samples (Ballabio and Consonni, 2013). This yielded 14 metabolites sufficient for explaining 71% of the variance in metabolites and 40% of the variance in treatments with 100% calibration accuracy and 100% cross-validation accuracy (Figure 1D). PLS-DA predicted that antibiotic-associated metabolic changes were most strongly characterized by depletion in uridine diphosphate (UDP), glucose-6-phosphate (G6P), and ribulose-5-phosphate (Ru5P) (Figure 1E). By inspection, many of these metabolites are intermediates in the pentose phosphate pathway, glycolysis, and fatty acid biosynthesis. We performed metabolite set enrichment analysis (MSEA) on these metabolites and found enrichment for “carbohydrate biosynthesis” (p = 6.47 × 10^-4) (Table S2).

Performing a similar analysis on the plasma and lung samples, we found different metabolite signatures associated with each tissue (Figures S1C and S1D). While MSEA identified lung metabolites as enriched for “generation of precursor metabolites and energy” (p = 3.46 × 10^-3) (Table S3), plasma metabolites were not specifically enriched for any metabolic pathways with false discovery rate (FDR)-corrected p values below significance (p = 0.05). We metabolomically profiled additional mice treated with a higher concentration of cipro (Figure S2A) and found that 400 μg/mL cipro mostly amplified the antibiotic-induced changes to host metabolites that we had observed at 100 μg/mL cipro in the peritoneum (Figures S2B and S2C) and plasma (Figures S2B and S2D), indicated by a further projection along the first principal component. Together, these data indicate that antibiotic treatment exerts tissue-specific changes in metabolites in the host environment.

**Antibiotic Treatment Elicits Microbiome-Independent Changes in Host Metabolites**

Antibiotics are thought to systemically alter metabolites in the host environment by acting on the gut microbiome (Reijnders et al., 2016), but the tissue-specific changes we observed suggested that antibiotics may instead act locally and directly on host cells. To test this hypothesis, we profiled metabolites from GF mice treated with 100 μg/mL cipro delivered in the drinking water (Figure 2A). Surprisingly, we found that many of the tissue-specific changes in metabolites from the conventional (CONV) mice also occurred in the GF mice lacking a microbiome (Figure 2B).

To better understand whether the antibiotic-induced changes to local metabolites in the CONV mice were due to direct effects on host cells versus effects on the microbiome, we performed PCA on CTL and ABX samples from both the CONV and GF mice for each tissue. PCA orthogonally clustered the peritoneal samples into four distinct quadrants along two principal components that captured 74% of the variance and appeared to directly correspond to presence of either a microbiome (PC 1) or antibiotic treatment (PC 2) (Figure 2C). Moreover, inspection of metabolites with the greatest PLS-DA loadings in the peritoneal ABX signature revealed similar fold changes in both CONV and GF mice, despite differences in the untreated CTL concentrations. PCA on the plasma samples similarly revealed that 83% of the variance in plasma metabolites could be explained by direct effects on host cells instead of effects on the microbiome (Figure 2D). In contrast, the lung samples did not separate as cleanly along principal components corresponding to a microbiome and antibiotic treatment (Figure S3). Together, these data indicate that most of the antibiotic-induced changes in metabolites are microbiome independent and likely due to direct actions of antibiotics on local host cells.

**Antibiotic Treatment Elicits Unique Metabolic Changes in the Presence of Infection**

Because antibiotics are administered to treat infection, we sought to characterize metabolic changes that occur in the presence of infection. We first identified an infection-specific metabolic signature by multivariate analysis and then tested whether the complex changes observed under combination treatment could be explained by the ABX and INF signatures. We performed elastic net regularization and used PLS-DA to discriminate the INF samples from the union of CTL and ABX samples, identifying a feature set of nine metabolites sufficient for explaining 90% of the variance in metabolites and 44% of the variance in treatments with 100% calibration accuracy and
100% cross-validation accuracy (Figure 3A). These were most strongly characterized by enrichment in guanosine monophosphate (gmp) and depletion in adenosine (adn) and AMP (amp) (Figure 3B). MSEA revealed that these were specifically enriched for purine metabolic pathways, including terms such as “purine nucleotide degradation” (p = 1.42e−6) and “purine nucleotide biosynthesis” (p = 1.96e−6) (Table S4). Because purine metabolites can function as important immune signaling molecules (Cekic and Linden, 2016), these data suggest that the INF metabolite signature indicated a local induction of host immunity.

PLS-DA of the peritoneal samples from all four treatment groups onto the union of metabolites from the ABX and INF signatures revealed that antibiotic treatment and infection formed two orthogonal dimensions describing the infection microenvironment with 88% calibration accuracy and 83% cross-validation accuracy (Figure 3C), in close agreement with the unsupervised PCA of these samples (Figure 1C). This was supported by the observation that udp, g6p, and ru5p under combination treatment trended similarly to antibiotic treatment, and gmp and adn trended similarly to infection (Figure 3B). Collectively, these results suggest that most of the local changes in host metabolites associated with antibiotic treatment of infection could be explained by the independent actions of either antibiotic treatment or infection.

Interestingly, not all of the metabolite changes in the COMB samples could be explained by the independent actions of
antibiotics or infection. For instance, amp was significantly enriched in the COMB samples despite being depleted in the INF samples and unchanged in the ABX samples (Figure 3B). We subjected additional mice to both infection and antibiotic treatment and sampled the peritoneum at earlier time points. We found that amp concentrations peaked at ~3-fold 6 hr after infection (Figure S4). COMB samples also scored higher than the ABX samples on the antibiotic axis (LV 2), suggesting that infection may potentiate the metabolic changes elicited by antibiotic treatment (Figure 3C). To test this, we performed elastic net regularization and used PLS-DA to identify a COMB-specific metabolite signature discriminating the COMB samples from the union of CTL, ABX, and INF samples. This comprised 20 metabolites sufficient for explaining 55% of the variance in metabolites and 35% of the variance in treatments with 100% calibration accuracy and 96% cross-validation accuracy (Figure 3D). PLS-DA predicted that this signature was enriched for thymine (thym) and amp, and depleted in 3-phospho-D-glyceroyl phosphate (23dpg) and guanosine (gsn) (Figures 3E and 3B). MSEA revealed these to be enriched in diverse metabolic processes, including

Figure 2. Antibiotic Treatment Elicits Microbiome-Independent Changes in Host Metabolites
(A) Experimental design for germ-free (GF) metabolomic profiling. GF mice were subjected to antibiotic treatment with 100 μg/mL cipro (ABX) and sampled 24 hr later.
(B) Hierarchically clustered heatmaps for changes in metabolite concentrations between ABX and control (CTL) mice, by tissue sample.
(C) Left: PCA projection of metabolomic profiles from CTL and ABX conventional (CONV) and GF mice in the peritoneum. Right: concentrations for peritoneal metabolites with large peritoneal ABX LV1 loadings in CONV and GF mice.
(D) Left: PCA projection of metabolomic profiles from CTL and ABX conventional (CONV) and GF mice in the plasma. Right: concentrations for plasma metabolites with large plasma ABX LV1 loadings in CONV and GF mice.
Data are presented as mean ± SEM from n = 3 independent biological replicates. Significance reported as FDR-corrected p values in comparison with corresponding CTL conditions: **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
various nucleotide, energy, and amino acid metabolism pathways (Table S5).

**Metabolites Altered by Antibiotic Treatment during Infection Inhibit Drug Efficacy**

Antibiotic efficacy is sensitive to the abundance of extracellular metabolites (Allison et al., 2011; Meylan et al., 2017). We hypothesized that host metabolites induced by antibiotic treatment of infection might feed back on drug susceptibility in the pathogen. To test this hypothesis, we quantified the minimum inhibitory concentration (MIC) of cipro in *E. coli* cells following 10 mM supplementation with thym or amp, which was ~13 ng/mL without supplementation. While thym supplementation did not appear to alter the MIC (~13.5 ng/mL), amp supplementation significantly decreased cipro susceptibility, increasing the MIC to ~100 ng/mL (Figure 4A). Time-kill experiments with 25 ng/mL cipro revealed that amp supplementation elicited dose-dependent protection (Figure 4B).

We further characterized changes in MIC promoted by supplementation with metabolites from the COMB, ABX, or INF signatures and found that many of these metabolites also inhibited drug susceptibility (Figures 4A, 4C, and 4D). MSEA on these
metabolites identified “amines and polyamines biosynthesis” as the metabolic pathway most enriched by these metabolites \((p = 3.99 \times 10^{-4})\) (Table S6). Together, these results demonstrate that host metabolites induced by antibiotics during treatment of infection can feed back and affect antibiotic efficacy.

**Direct Actions of Antibiotic Treatment on Immune Cells Inhibit Phagocytic Killing**

Bactericidal antibiotics can impair mitochondrial function in epithelial cells and inhibit their respiratory activity (Kalghatgi et al., 2013). In addition, metabolites present in the host microenvironment may initiate signaling cascades in immune cells that lead to metabolic reprogramming and functional changes (O’Neill and Hardie, 2013). Because efficient phagocytosis involves induction of a highly energy-dependent respiratory burst (Murphy and Weaver, 2016), we sought to determine whether antibiotic treatment might also interfere with the respiratory activity of immune cells. We pre-treated mouse macrophages with cipro and measured changes in oxygen consumption following electron transport chain uncoupling (Figure 5A). These data revealed a dose-dependent inhibition of respiratory capacity (Figure 5B).

We hypothesized that antibiotic-induced impairments in respiration and/or the induction of local metabolites might physiologically alter the phagocytic activity of immune cells recruited to a site of infection. To test this hypothesis, we enumerated *E. coli* cells attached or killed by macrophages following treatment with cipro and/or amp. Compared with untreated cells, macrophages pre-treated with 20 \(\mu\)g/mL cipro for 3 hr (ABX) engulfed fewer *E. coli* cells (Figures 5C and S5A) and possessed more surviving cells following lyisis of the macrophages (Figures 5D and S5B), indicating a significant decrease in the killing of engulfed cells (Figure 5E). In contrast, we found that 10 mM amp significantly increased pathogen engulfment (Figures 5C and S5C) and decreased pathogen survival (Figures 5D and S5D), indicating that metabolites induced at the site of infection by antibiotics may feed forward and potentiate immune function. Interestingly, antibiotic treatment exerted a dominant-negative effect over the metabolic potentiation in macrophages subjected to both cipro and amp (ABX + amp), most prominently in the ability to engulf pathogens. Collectively, these results indicate that antibiotic treatment can directly act on immune cells and metabolically impair their function.

**DISCUSSION**

Infections are complex host-microbe interfaces composed of multiple species, cell types, and biochemical species. While local metabolism is understood to be important for pathogens to establish their niche, the contribution of antibiotics to this environment is poorly understood. Here, we investigated the effects of antibiotic treatment on host metabolism in a commonly used and well-defined model of *in vivo* infection. While antibiotics normally act in concert with host immune cells to remove pathogens...
at a site of infection, we report that antibiotics also act synergistically with pathogen cells to remodel the local metabolic environment (Figure 6). We demonstrate that metabolites induced in this environment have the capacity to affect both antibiotic efficacy and immune function and that the direct consequences of antibiotics on the metabolism of immune cells can inhibit their phagocytic activity. These data highlight the complex interactions elicited by antibiotics at the site of infection and support prior in vitro studies demonstrating that the host metabolic environment is critical for the function of both antibiotics (Yang et al., 2017) and immune cells (Buck et al., 2017).

Antibiotics are thought to systemically alter metabolites in the host by manipulating gut microbiome taxonomy (Reijnders et al., 2016). We report that orally administered antibiotics also induce dose-dependent and microbiome-independent changes in metabolites in the host environment. Of significance, we find that most of the metabolic variation observed in conventionally raised mice also appeared in GF mice in both the plasma and peritoneum. These results are consistent with our previous observations that bactericidal antibiotics directly induce mitochondrial dysfunction in mammalian cells (Kalghatgi et al., 2013) and our present observations that antibiotics can inhibit the phagocytic activity of immune cells, which require a functioning respiratory chain for their bactericidal oxidative burst. In our in vitro experiments, these effects appeared to occur at concentrations $\geq 1 \mu M$, well within the pharmacokinetic range of 1–5 $\mu M$ achieved in human serum following oral delivery and $\geq 10 \mu M$ in other tissues following intravenous delivery (Vance-Bryan et al., 1990).

Nutrient availability at a site of infection is an important regulator of antibiotic susceptibility (Amato et al., 2014), and previous studies have demonstrated that antibiotic tolerance may be overcome metabolically by stimulating bacterial central metabolism (Allison et al., 2011; Meylan et al., 2017). We report that diverse metabolites induced by antibiotics at the site of infection also have the potential to alter both antibiotic efficacy and immune function. An example of this is in the synergistic and local induction of AMP, an energy currency precursor and a participant in purine metabolism that exerts immunomodulation through AMP-activated protein kinase (O’Neill and Hardie, 2013). We find that AMP alters E. coli sensitivity to cipro and enhances phagocytic killing by macrophages. Although the AMP concentrations that we measured from our bulk lavage of the peritoneum ($\leq 10^{-5} - 10^{-6} \mu M$) did not exceed the $>100 \mu M$ required to elicit an effect on either antibiotic efficacy or immune function, it is possible that AMP concentrations were higher in regional peritoneal microdomains due to the large surface area and complex geometry of the peritoneum. Moreover, AMP concentrations are generally $\leq 200 \mu M$ in mammalian tissues (Traut, 1994) and can increase >100-fold in human tissues following metabolically demanding activities such as exercise (Harkness et al., 1983). AMP therefore may have more significant effects in other tissues or other in vivo infection models.

While here we use AMP to exemplify a single form of complex metabolic crosstalk between host and microbe physiology in the context of infection, other metabolites altered at a site of infection likely also significantly affect antibiotic efficacy or immune function through undiscovered mechanisms. MSEA identified polyamine biosynthesis as a metabolic process enriched by the protective metabolites from our metabolite screens. Interestingly, several studies demonstrate that polyamines can protect pathogens against antibiotic treatment (Kwon and Lu, 2006) by

Figure 5. Direct Actions of Antibiotic Treatment on Immune Cells Inhibit Phagocytic Killing
(A) Changes in macrophage oxygen consumption rate in control (CTL) and cells pre-treated for 3 hr with cipro, following electron transport chain uncoupling by 2 $\mu M$ oligomycin, 1 $\mu M$ FCCP (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone), and 0.5 $\mu M$ rotenone + antimycin A.
(B) Changes in respiratory capacity following cipro pre-treatment.
(C) Pathogen engulfment by control (CTL) or macrophages treated with $20 \mu g/mL$ cipro (ABX), $10 \mu M$ AMP (amp), or their combination (ABX + amp).
(D) Pathogen survival in CTL, ABX, amp, or ABX + amp macrophages.
(E) Phagocytic killing by CTL, ABX, amp, or ABX + amp macrophages.

Data are presented as mean ± SEM from $n \geq 3$ independent biological replicates. Significance reported as FDR-corrected $p$ values within the indicated comparisons: $^*p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$, $^{****}p < 0.0001$.
Figure 6. Metabolic Effects of Antibiotic Treatment on Host Cells Inhibit Drug Efficacy and Impair Immune Function

During infection, antibiotics work in concert with immune cells to clear microbial pathogens (black lines). Meanwhile, antibiotics and pathogen cells metabolically remodel the local infectious microenvironment by acting on local host cells (dashed lines). Induced metabolites can inhibit drug efficacy and potentiate immune function (purple lines). Direct actions by antibiotics on immune cell metabolism can also impair immune cell phagocytic activity (red line).

Finally, our work identifies the local metabolic microenvironment as an important determinant in the resolution of infection, due to its actions on antibiotic susceptibility and immune function. It is likely that interpersonal differences in the combination of such metabolites may contribute to variable treatment outcomes across patients suffering from similar infections (Lee and Collins, 2011). Additionally, dynamic changes to these environments, for instance by prophylactics, may be useful for maximizing both antibiotic efficacy and immune function. As recognition of metabolic context dependence for antibiotic efficacy is growing for important human pathogens (Black et al., 2014), our findings support the use of metabolic adjuvants to enhance our existing antibiotic arsenal (Wright, 2016).

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Bacterial Strains, Media, Growth Conditions
  - Vertebrate Animals
  - Cell Lines
- **METHOD DETAILS**
  - Materials and Reagents
  - Animal Experiments
  - Metabolomic Profiling
  - Minimum Inhibitory Concentrations
  - Time-Kill Experiments
  - Macrophage Assays
  - Oxygen Consumption Rate Quantification
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - Experimental Replicates
- **O Metabolite Quantification**
- **O Multivariate Analysis**
- **O Metabolite Set Enrichment Analysis**
- **O Statistical Analysis**

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes five figures and six tables and can be found with this article online at https://doi.org/10.1016/j.chom.2017.10.020.

**AUTHOR CONTRIBUTIONS**


**ACKNOWLEDGMENTS**

This work was supported by grant HDTRA1-15-1-0051 from the Defense Threat Reduction Agency, grants K99GM118807 and U01AI124316 from the NIH, grant NNF16CC0021858 from the Novo Nordisk Foundation, the Paul G. Allen Frontiers Group, and the Wyss Institute for Biologically Inspired Engineering. The authors thank Dr. Lynn Bry and the Gnotobiotic and Microbiology Core Facility of the Massachusetts Host-Microbiome Center at Brigham and Women’s Hospital for their assistance in performing experiments on the GF mice. Immortalized SV129 mouse macrophages were generously gifted by Dr. Chih-Hao Lee (Harvard Chan School of Public Health). J.J.C. is scientific co-founder and scientific advisory board chair of Enbiotix, an antibiotics startup company.

Received: March 20, 2017
Revised: September 1, 2017
Accepted: October 27, 2017
Published: November 30, 2017

**REFERENCES**


KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacterial and Virus Strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>ATCC</td>
<td>ATCC 25922</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Sigma-Aldrich</td>
<td>Cat# 17850-25G-F; CAS: 85721-33-1</td>
</tr>
<tr>
<td>Adenosine 5’-monophosphate</td>
<td>Acros Organics (Fisher Scientific)</td>
<td>Cat# AC102790050; CAS: 61-19-8</td>
</tr>
<tr>
<td><strong>Critical Commercial Assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seahorse XF Cell Mito Stress Test Kit</td>
<td>Seahorse Bioscience</td>
<td>Cat# 103015-100</td>
</tr>
<tr>
<td><strong>Experimental Models: Cell Lines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Mus musculus</em> (SV129) macrophages</td>
<td>(Lee et al., 2006)</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Experimental Models: Organisms/Strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Mus musculus</em> (C57BL/6J)</td>
<td>Jackson Labs</td>
<td>000664</td>
</tr>
<tr>
<td><strong>Software and Algorithms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AB SCIEX MultiQuant v. 3.0</td>
<td>SCIEX</td>
<td>N/A</td>
</tr>
<tr>
<td>Amelia II v. 1.7.4</td>
<td>(Honaker et al., 2011)</td>
<td>N/A</td>
</tr>
<tr>
<td>LMGene v. 3.3</td>
<td>(Lu et al., 2008)</td>
<td>N/A</td>
</tr>
<tr>
<td>MATLAB 2016b</td>
<td>MathWorks</td>
<td>N/A</td>
</tr>
<tr>
<td>Classification Toolbox v. 4.0</td>
<td>(Ballabio and Consonni, 2013)</td>
<td>N/A</td>
</tr>
<tr>
<td>Ecocyc v. 20.1</td>
<td>(Keseler et al., 2017)</td>
<td>N/A</td>
</tr>
<tr>
<td>Prism v. 7.0b</td>
<td>GraphPad</td>
<td>N/A</td>
</tr>
</tbody>
</table>

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, James J. Collins (jimjc@mit.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

**Bacterial Strains, Media, Growth Conditions**
*Escherichia coli* strain ATCC25922 was purchased from the American Type Culture Collection (ATCC) and used for all experiments in this study. Cells were cultured in tryptic soy broth (TSB) and grown at 37°C on a rotating shaker at 300 rpm in flasks or 14 mL test tubes or at 900 rpm in 96-well plates.

**Vertebrate Animals**
Conventional and germ-free 8-week old male C57BL/6J mice were acquired from Jackson Labs (Bar Harbor, ME) and used for all experiments in this study. They were housed at the Harvard Institute of Medicine Vivarium and germ-free mice were housed at the Gnotobiotic and Microbiology Core Facility at Brigham and Women’s Hospital. All mice were socially housed and monitored daily for 7 days before experiments to permit acclimatization. Following intra-peritoneal infection and/or antibiotic treatment, mice were monitored twice for signs of dehydration and water intake and observed for signs of potential pain or distress associated with any intestinal discomfort. Animal protocols for the experiments performed in this study were approved by the Harvard Medical School Institutional Animal Care and Use Committee and all experiments conform to relevant regulatory standards.

**Cell Lines**
Immortalized mouse SV129 macrophages were derived from a bone marrow cell line from male SV129 mice and authenticated by qPCR (Lee et al., 2006). Macrophages were maintained in 1 g/L glucose DMEM (Cell-Gro; Manassas, VA) supplemented with 10% FBS and 1% penicillin/streptomycin. SV129 macrophages were loaded onto 24-well tissue culture treated plates at 5·10^5 macrophages/well the day before experiment.
**METHOD DETAILS**

**Materials and Reagents**
Ciprofloxacin (cipro) and all metabolites used as metabolic perturbations or metabolomic profiling standards were purchased from Sigma-Aldrich (St. Louis, MO). BD Difco TSB and tryptic soy agar were purchased from Fisher Scientific (Hampton, NH). Uniformly labeled $^{13}$C glucose was purchased from Cambridge Isotope Laboratories (Tewksbury, MA). LC-MS reagents were purchased from Honeywell Burdick & Jackson (Muskegon, MI) and Sigma-Aldrich.

**Animal Experiments**
8-week old male C57BL/6J mice were intraperitoneally injected with $10^7$ CFU *E. coli* cells in sterile saline. Control water or drinking water containing 100 or 400 µg/mL cipro was introduced 4 h post infection. These concentrations were selected based on an estimate that a typical 25 g mouse drinks 4 mL of water each day, yielding a daily dose of 16 or 64 mg/kg/day cipro, which is in the 10-250 mg/kg/day range typically used to treat humans. Mice were sacrificed 20 h later; blood was harvested by cardiac puncture and plasma was isolated using lithium heparin tubes (Greiner Bio-One; Kremsmünster, Austria), according to the manufacturer’s instructions. The peritoneum was lavaged with 5 mL sterile PBS in 2.5 mL increments. The lung was lavaged through the trachea with 5 mL sterile PBS in 0.7 mL increments. All samples were kept on ice following collection.

**Metabolomic Profiling**
Metabolites were acquired and quantified on an AB SCIEX Qtrap 5500 mass spectrometer (AB SCIEX; Framingham, MA) and processed using MultiQuant 3.0.1, as described previously (McCloskey et al., 2015). Metabolite extractions were performed using a 40:40:20 mixture of acetonitrile, methanol and LC-MS grade water in Phree Phospholipid Removal tubes (Phenomenex; Torrance, CA). Uniformly labeled $^{13}$C-standards were generated by growing *E. coli* in uniformly labeled Glucose M9 minimal media in aerated shake flasks, as previously described (McCloskey et al., 2014). Calibration mixes of standards were split across several mixes, aliquoted, and lyophilized to dryness. All samples and calibrators were equally spiked with the same internal standards. Samples were quantified using isotope-dependent mass spectrometry. Calibration curves were run before and after all biological and analytical replicates. Consistency of quantification between calibration curves was checked by running a Quality Control sample composed of all biological replicates. Values reported are derived from the average of the biological triplicates, analyzed in duplicate (n = 6).

**Minimum Inhibitory Concentrations**
Minimum Inhibitory Concentrations (MICs) were determined by microbroth dilution in 96-well microtiter plates with 1.5-fold step sizes of cipro dissolved in TSB, as previously described (Andrews, 2001). Approximately $10^4$ CFU *E. coli* suspended in TSB supplemented with 2-20 mM of each metabolite were added to each well of the 96-well plates to achieve a total volume of 200 µL. Plates were sealed with a breathable membrane and then incubated at 37 °C with 900 rpm shaking for 20 h. Following incubation, OD$_{600}$ was quantified on a SpectraMax M3 plate reader. MIC experiments were performed in at least triplicate from independent overnight cultures with values reported as the mean ± SEM.

**Time-Kill Experiments**
Time-kill experiments were performed as previously described (Dwyer et al., 2014). Briefly, an overnight culture of *E. coli* cells in TSB was diluted 1:1,000 and grown to OD$_{600}$ ~0.1 at 37 °C with 300 rpm shaking prior to experiment. 1 mL cultures were then dispensed to 14 mL test tubes and treated with cipro and/or amp. Hourly samples were collected and serially diluted in PBS for colony enumeration 24 h later.

**Macrophage Assays**
*In vitro* phagocytosis assays were adapted from previously published protocols (Sokolovska et al., 2012) and performed using SV129 macrophages. On the day of experiment, culture media was replaced with 1 g/L DMEM supplemented with 1% FBS. *E. coli* cells grown to OD$_{600}$ ~0.3 in TSB and antibiotics were added to macrophages on ice for 30 min to synchronize phagocytosis. Plates were then incubated at 37 °C for 30 min with a control plate maintained on ice to quantify *E. coli* cells engulfed, but not killed. Cells were washed thrice with PBS + 0.5 mM EDTA. Cells were lysed with pH 11.5 H$_2$O for 4 min and serially diluted for colony enumeration 24 h later.

**Oxygen Consumption Rate Quantification**
Macrophage respiratory activity was quantified using the Seahorse XF Cell Mito Stress Test Kit and XF®96 Extracellular Flux Analyzer (Seahorse Bioscience; North Billerica, MA), according to the manufacturer’s instructions. Briefly, SV129 macrophages were plated at a density of 125,000 cells per well and cultured overnight before the start of the experiment. Cells were PBS washed and then pre-treated with cipro for 3 h in the XF Base Medium (Seahorse Bioscience; North Billerica, MA). The Mito Stress Test Kit assay was then performed using 2 µM oligomycin, 1 µM FCCP and 0.5 µM rotenone/antimycin A. Respiratory capacity was computed as the difference in oxygen consumption rate following FCCP treatment and following rotenone/antimycin A.
QUANTIFICATION AND STATISTICAL ANALYSIS

Experimental Replicates
All in vivo metabolomic quantification experiments were performed using n = 3 mice in each treatment condition, with samples prepared in technical duplicate, yielding n = 6 samples for each condition. In vitro MIC estimations following metabolite supplementations were performed using n = 3-6 biological replicates of E. coli cells on different days. Time-kill experiments involving E. coli cells were performed in biological triplicate on different days. Oxygen consumption experiments were performed in biological triplicate with n = 5 technical replicates in different wells of the 96-well Seahorse cartridges on different days. In vitro measurements of immune function using SV129 mouse macrophages were performed with n = 3-4 biological replicates on different days, with n = 4 technical replicates on 24-well tissue-culture treated plates.

Metabolite Quantification
Metabolite concentrations were estimated from LC-MS/MS peak heights using previously generated calibration curves. Metabolites found to have a quantifiable variability (RSD ≥ 50%) in the Quality Control samples or possessing individual components with a RSD ≥ 80% were excluded from analysis. Metabolites in blanks with a concentration greater than 80% of that found in the biological samples were similarly excluded. Missing values were imputed by bootstrapping using the R package Amelia II (v. 1.7.4, 1,000 imputations) (Honaker et al., 2011). Remaining missing values were approximated as ½ the lower limit of quantification for the metabolite normalized to the biomass of the sample. Metabolite concentrations from the peritoneum and lung were scaled 300- and 125-fold, respectively, to account for the dilution effect by a 5 mL lavage based on estimated peritoneal fluid volume of ~16 µL (Hartveit and Thunold, 1966) and estimated lung alveolar fluid volume of ~40 µL (Korfhagen et al., 1996).

Multivariate Analysis
Metabolite concentrations were first pre-processed with the generalized log transformation using the R package LMGene (v. 3.3) (Lu et al., 2008) and then centered to achieve an approximately normal distribution. Hierarchical clustering, principal components analysis and elastic net regularization were performed in MATLAB 2016b (MathWorks; Natick, MA). Partial least squares discriminant analysis was performed using the MATLAB package Classification Toolbox (v. 4.0) (Ballabio and Consonni, 2013).

Metabolite Set Enrichment Analysis
Metabolite Set Enrichment Analysis (MSEA) was performed in Ecocyc (v. 20.1) (Keseler et al., 2017). SmartTables were created comprised of metabolites from each metabolite signature and pathways were identified using the “Enrichment and Depletion” analysis type. The Fisher Exact test was performed for each enrichment analysis with FDR correction by the Benjamini-Hochberg method.

Statistical Analysis
Statistical significance testing was performed in Prism v7.0b (Graphpad; San Diego, CA). One-way ANOVA was performed on data from all experiments. Reported p-values reflect false-discovery correction by the Holm-Sidak multiple comparisons test, with comparisons against either only the relevant control condition, or only against specific other conditions as indicated. Although ANOVA is generally robust against lack of normality in the data, statistical tests were not specifically performed to determine if all of the assumptions of ANOVA had been met.